PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsRitonavir
Norvir(ritonavir)
Kaletra, Norvir, Paxlovid, Ritonavir, Technivie, Viekira, Viekirax (ritonavir) is a small molecule pharmaceutical. Ritonavir was first approved as Norvir on 1996-03-01. It is used to treat acquired immunodeficiency syndrome in the USA. It has been approved in Europe to treat chronic hepatitis c and HIV infections. It is known to target UDP-glucuronosyltransferase 1A1, cytochrome P450 3A5, and cytochrome P450 3A4.
Download report
Favorite
COVID-19
Case Study: COVID-19
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
urogenital diseasesD000091642
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Norvir, Ritonavir (discontinued: Norvir, Ritonavir)
Combinations
Kaletra, Lopinavir ritonavir, Paxlovid (discontinued: Kaletra, Technivie, Viekira)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lopinavir
+
Ritonavir
Tradename
Company
Number
Date
Products
KALETRAAbbVieN-021251 RX2000-09-15
1 products, RLD, RS
KALETRAAbbVieN-021906 RX2005-10-28
2 products, RLD, RS
Show 1 discontinued
Ritonavir
Tradename
Company
Number
Date
Products
NORVIRAbbVieN-022417 RX2010-02-10
1 products, RLD, RS
NORVIRAbbVieN-209512 RX2017-06-07
1 products, RLD, RS
Show 3 discontinued
Ombitasvir
+
Paritaprevir
+
Ritonavir
Tradename
Company
Number
Date
Products
TECHNIVIEAbbVieN-207931 DISCN2015-07-24
1 products, RLD
Hide discontinued
Dasabuvir sodium
+
Ombitasvir
+
Paritaprevir
+
Ritonavir
Tradename
Company
Number
Date
Products
VIEKIRA PAK (COPACKAGED)AbbVieN-206619 DISCN2014-12-19
1 products, RLD
VIEKIRA XRAbbVieN-208624 DISCN2016-07-22
1 products, RLD
Hide discontinued
Nirmatrelvir
+
Ritonavir
Tradename
Company
Number
Date
Products
PAXLOVID (COPACKAGED)PfizerN-217188 RX2023-05-25
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
kaletraNew Drug Application2023-07-06
lopinavir and ritonavirANDA2023-10-20
lopinavir-ritonavirANDA2020-11-18
norvirNew Drug Application2024-07-03
paxlovidNew Drug Application2025-07-09
ritonavirANDA2025-09-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acquired immunodeficiency syndromeEFO_0000765D000163B20
hepatitis c—D006526B19.2
chronic hepatitis cEFO_0004220D019698B18.2
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Dasabuvir Sodium / Ombitasvir / Paritaprevir / Ritonavir, Viekira Xr, Abbvie
93332042035-01-02DPU-1889
97441702035-01-02DPU-1889
101053652035-01-02DPU-1889
102015412032-05-17DP
102015842032-05-17U-1889
Dasabuvir Sodium / Ombitasvir / Paritaprevir / Ritonavir, Viekira Pak (Copackaged), Abbvie
96298412033-10-18DPU-1753
102015422033-10-18DPU-1753
84661592032-09-04U-1637
84923862032-09-04U-1840
86801062032-09-04U-1637
86859842032-09-04U-1840
86919382032-04-13DS, DP
86860262031-06-09DP
84205962031-04-10DS, DP
90444802031-04-10U-1638
90063872030-06-10U-1687
86425382029-09-10DS, DPU-1638
81881042029-05-17DS, DPU-1636
85012382028-12-19DS, DPU-1636
91395362028-11-09U-1753
82683492024-08-25DP
83990152024-08-25DP
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AE: Protease inhibitors, direct acting antivirals
— J05AE03: Ritonavir
— J05AP: Antivirals for treatment of hcv infections
— J05AP52: Dasabuvir, ombitasvir, paritaprevir and ritonavir
— J05AP53: Ombitasvir, paritaprevir and ritonavir
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR10: Lopinavir and ritonavir
— J05AR23: Atazanavir and ritonavir
— J05AR26: Darunavir and ritonavir
HCPCS
No data
Clinical
Clinical Trials
1192 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis cD006526—B19.2192761960
Chronic hepatitis cD019698EFO_0004220B18.2—82361752
HepatitisD006505—K75.9—11421935
Hepatitis aD006506EFO_0007305B15—11421935
InfectionsD007239EFO_0000544——1111—12
Hiv infectionsD015658EFO_0000764B20—11225
CoinfectionD060085—————1—1
Hepatitis virusesD006518—————1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic hepatitisD006521—K73.9—210—1526
Chronic hepatitis bD019694EFO_0004239B18.1—58——12
HepacivirusD016174———27—110
Liver cirrhosisD008103EFO_0001422K74.0—24—16
FibrosisD005355———14—16
Communicable diseasesD003141———14——4
Kidney diseasesD007674EFO_0003086N08——3——3
Acquired immunodeficiency syndromeD000163EFO_0000765B20—11—12
Chronic kidney failureD007676EFO_0003884N18.6——2——2
Renal insufficiencyD051437—N19——2——2
Show 4 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382—U07.1—1———1
Coronavirus infectionsD018352EFO_0007224B34.2—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRitonavir
INNritonavir
Description
Ritonavir is an L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver. It has a role as an antiviral drug, a HIV protease inhibitor, an environmental contaminant and a xenobiotic. It is a member of 1,3-thiazoles, a L-valine derivative, a carbamate ester, a member of ureas and a carboxamide.
Classification
Small molecule
Drug classantivirals: HIV protease inhibitors (saquinavir type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
Identifiers
PDB—
CAS-ID155213-67-5
RxCUI—
ChEMBL IDCHEMBL163
ChEBI ID45409
PubChem CID392622
DrugBankDB00503
UNII IDO3J8G9O825 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CYP3A4
CYP3A4
Organism
Homo sapiens
Gene name
CYP3A4
Gene synonyms
CYP3A3
NCBI Gene ID
1576
Protein name
cytochrome P450 3A4
Protein synonyms
1,4-cineole 2-exo-monooxygenase, 1,8-cineole 2-exo-monooxygenase, Albendazole monooxygenase (sulfoxide-forming), Albendazole sulfoxidase, Cholesterol 25-hydroxylase, CYPIIIA3, CYPIIIA4, Cytochrome P450 3A3, Cytochrome P450 HLp, Cytochrome P450 NF-25, cytochrome P450, family 3, subfamily A, polypeptide 4, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, Cytochrome P450-PCN1, glucocorticoid-inducible P450, Nifedipine oxidase, P450-III, steroid inducible, Quinine 3-monooxygenase, taurochenodeoxycholate 6-alpha-hydroxylase
Uniprot ID
P08684
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Viekira – AbbVie
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Norvir – AbbVie
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Kaletra – AbbVie
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Paxlovid – Pfizer
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Ritonavir
+
Lopinavir
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Ritonavir
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 47,535 documents
View more details
Safety
Black-box Warning
Black-box warning for: Norvir, Paxlovid, Ritonavir
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
106,920 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use